Sanford C. Bernstein reiterated their market perform rating on shares of Biogen Idec (NASDAQ: BIIB) in a research note released on Wednesday morning, Stock Ratings Network.com reports. They currently have a $231.00 target price on the stock.
Several other analysts have also recently commented on the stock. Analysts at Citigroup Inc. upgraded shares of Biogen Idec from a neutral rating to a buy rating in a research note to investors on Monday. Separately, analysts at Piper Jaffray Cos. reiterated a neutral rating on shares of Biogen Idec in a research note to investors on Monday, July 1st. They now have a $251.00 price target on the stock, up previously from $229.00.
Ten investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Biogen Idec has an average rating of Buy and a consensus target price of $236.32.
Biogen Idec (NASDAQ: BIIB) traded down 0.68% on Wednesday, hitting $221.78. Biogen Idec has a 52-week low of $134.00 and a 52-week high of $242.64. The stock’s 50-day moving average is currently $218.4. The company has a market cap of $52.645 billion and a price-to-earnings ratio of 35.43.
Biogen Idec Inc (NASDAQ: BIIB) is a global biotechnology company.